CD274 and familial pancreatic carcinoma: In summary, the combination of PDL1/PD-1 inhibitors with FOLFIRINOX regimens has shown longer survival than treatment with FOLFIRINOX regimens for pancreatic cancer patients, with reliable clinical efficacy, tolerable adverse effects, and a high safety profile.